Researchers Find Sildenafil, the Active Ingredient in Viagra, May Slow Cancer Spread
A study published in July 2026 found that sildenafil, the active ingredient in Viagra, may help slow the spread of certain cancers. Researchers found the drug interferes with a mechanism cancer cells use to migrate through the body. The findings add to a growing body of research exploring existing drugs for new medical uses.
Researchers have found that sildenafil, the active ingredient in Viagra, may help slow the spread of certain cancers, according to a study published in July 2026.
The drug, originally developed to treat erectile dysfunction and pulmonary arterial hypertension, appears to interfere with a mechanism that cancer cells use to migrate through the body. The findings were reported by Healthline and are part of a broader wave of research exploring whether existing, well-understood drugs can be repurposed for cancer treatment.
Sildenafil works by inhibiting an enzyme called phosphodiesterase type 5 (PDE5), which relaxes smooth muscle tissue and increases blood flow. Researchers believe this same mechanism may disrupt the signaling pathways that allow cancer cells to spread from a primary tumor to other parts of the body.
The study adds to earlier research suggesting sildenafil may have anti-cancer properties. Previous laboratory studies had shown the drug could enhance the effectiveness of certain chemotherapy agents.
Researchers cautioned that the findings are preliminary and that clinical trials would be needed before sildenafil could be recommended as a cancer treatment. The drug is not without side effects, and its interaction with cancer therapies would need to be carefully studied.
The research reflects a growing interest in drug repurposing, an approach that can significantly reduce the time and cost of bringing new treatments to patients by building on the existing safety profiles of approved medications.
